Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
43,496,286
-
Total 13F shares
-
42,970,633
-
Share change
-
+4,153,172
-
Total reported value
-
$1,114,223,528
-
Price per share
-
$25.93
-
Number of holders
-
93
-
Value change
-
+$108,250,251
-
Number of buys
-
61
-
Number of sells
-
18
Institutional Holders of Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) as of Q3 2025
As of 30 Sep 2025,
Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) was held by
93 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,970,633 shares.
The largest 10 holders included
TRV GP IV, LLC, Frazier Life Sciences Management, L.P., ARCH Venture Management, LLC, Deep Track Capital, LP, Alphabet Inc., a16z Capital Management, L.L.C., Matrix Capital Management Company, LP, VANGUARD GROUP INC, BlackRock, Inc., and VR ADVISER, LLC.
This page lists
93
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.